Bayer

Bayer to pursue Nexavar patent case in Mumbai High court

Bayer to pursue Nexavar patent case in Mumbai High court

Bayer AG, Germany-based pharmaceuticals giant, declared on Monday that it would challenge the Indian Intellectual Property Appellate Board's decision regarding its anti-cancer drug Nexavar in high court.

The Controller General of Patents (CGP) allowed Hyderabad-based Natco to produce and sell a generic version of Bayer's anti-cancer drug Nexavar. The German pharmaceuticals company opposed the decision and took the matter to India's Intellectual Property Appellate Board (IPAB), which upheld the CGP's decision.